Burling Wealth Partners LLC Sells 11,537 Shares of AstraZeneca PLC $AZN

Burling Wealth Partners LLC cut its holdings in AstraZeneca PLC (NASDAQ:AZN) by 31.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 25,736 shares of the company’s stock after selling 11,537 shares during the quarter. Burling Wealth Partners LLC’s holdings in AstraZeneca were worth $1,974,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. NewSquare Capital LLC lifted its stake in AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after buying an additional 218 shares during the period. Rakuten Investment Management Inc. bought a new stake in shares of AstraZeneca in the 3rd quarter valued at about $31,000. E Fund Management Hong Kong Co. Ltd. raised its position in shares of AstraZeneca by 144.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock valued at $36,000 after acquiring an additional 275 shares during the period. VSM Wealth Advisory LLC bought a new position in AstraZeneca during the 2nd quarter worth approximately $33,000. Finally, FSA Wealth Management LLC grew its holdings in AstraZeneca by 376.0% during the second quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after purchasing an additional 376 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Trading Down 0.5%

NASDAQ AZN opened at $208.47 on Thursday. AstraZeneca PLC has a 52 week low of $122.48 and a 52 week high of $212.71. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. The stock’s 50 day moving average price is $119.74 and its two-hundred day moving average price is $95.74. The stock has a market capitalization of $323.32 billion, a price-to-earnings ratio of 69.26, a PEG ratio of 1.59 and a beta of 0.34.

AstraZeneca Announces Dividend

The firm also recently declared a dividend, which will be paid on Monday, March 23rd. Shareholders of record on Friday, February 20th will be given a dividend of $1.595 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a yield of 165.0%. AstraZeneca’s payout ratio is 74.83%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on AZN shares. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, January 21st. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of AstraZeneca in a report on Friday, February 6th. Jefferies Financial Group started coverage on AstraZeneca in a research report on Monday, October 27th. They issued a “buy” rating for the company. Finally, Wall Street Zen downgraded shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $95.75.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.